Casdin Capital, LLC Global Blood Therapeutics, Inc. Transaction History

Casdin Capital, LLC

$1.29 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$22.3 - $37.39 $11.7 Million - $19.6 Million	-525,000 Reduced 39.62%	800,000 $25.6 Million
Q4 2021 Feb 14, 2022	SELL	$24.9 - $40.26 $14.9 Million - $24.2 Million	-600,000 Reduced 31.17%	1,325,000 $38.8 Million
Q3 2021 Nov 15, 2021	BUY	$25.48 - $37.34 $15.7 Million - $23 Million	615,000 Added 46.95%	1,925,000 $49 Million
Q2 2021 Aug 16, 2021	BUY	$32.46 - $43.42 $13.3 Million - $17.8 Million	410,000 Added 45.56%	1,310,000 $45.9 Million
Q1 2021 May 17, 2021	BUY	$38.94 - $50.85 $3.5 Million - $4.58 Million	90,000 Added 11.11%	900,000 $36.7 Million
Q4 2020 Feb 16, 2021	BUY	$37.65 - $63.77 $15.6 Million - $26.5 Million	415,000 Added 105.06%	810,000 $35.1 Million
Q3 2020 Nov 16, 2020	BUY	$52.76 - $74.49 $5.01 Million - $7.08 Million	95,000 Added 31.67%	395,000 $21.8 Million
Q1 2019 May 15, 2019	SELL	$39.99 - $53.48 $2 Million - $2.67 Million	-50,000 Reduced 14.29%	300,000 $15.9 Million
Q4 2018 Feb 13, 2019	SELL	$31.54 - $46.67 $2.84 Million - $4.2 Million	-90,000 Reduced 20.45%	350,000 $14.4 Million
Q3 2018 Nov 14, 2018	SELL	$38.0 - $51.1 $1.52 Million - $2.04 Million	-40,000 Reduced 8.33%	440,000 $16.7 Million
Q2 2018 Aug 14, 2018	SELL	$38.7 - $50.15 $4.64 Million - $6.02 Million	-120,000 Reduced 20.0%	480,000 $21.7 Million
Q1 2018 May 15, 2018	BUY	$39.6 - $65.9 $3.37 Million - $5.6 Million	85,000 Added 16.5%	600,000 $29 Million
Q4 2017 Feb 14, 2018	BUY	$29.7 - $45.7 $4.01 Million - $6.17 Million	135,000 Added 35.53%	515,000 $20.3 Million
Q3 2017 Nov 14, 2017	BUY	$25.1 - $31.05 $9.54 Million - $11.8 Million	380,000	380,000 $11.8 Million

Others Institutions Holding GBT

# of Institutions

Shares Held

288K

Call Options Held

Put Options Held

View Full List

About Global Blood Therapeutics, Inc.

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

More about GBT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Casdin Capital, LLC with notifications on news.

Account